A number of other equities analysts have also recently commented on LIVN. Needham & Company LLC cut their target price on shares of LivaNova from $91.00 to $88.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Piper Jaffray Companies set a $90.00 price objective on shares of LivaNova and gave the company a “buy” rating in a research report on Friday, September 6th. BidaskClub lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 24th. BTIG Research restated a “hold” rating on shares of LivaNova in a research report on Wednesday, July 31st. Finally, Berenberg Bank restated a “buy” rating and set a $114.00 target price on shares of LivaNova in a research report on Monday, September 9th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $97.67.
LivaNova stock traded down $0.03 during midday trading on Thursday, hitting $73.33. 233,500 shares of the stock were exchanged, compared to its average volume of 484,997. The stock’s 50-day simple moving average is $73.26 and its 200 day simple moving average is $74.32. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of 23.13, a PEG ratio of 3.36 and a beta of 0.53. LivaNova has a fifty-two week low of $64.80 and a fifty-two week high of $126.99. The company has a current ratio of 1.17, a quick ratio of 0.81 and a debt-to-equity ratio of 0.21.
In related news, Director Daniel Jeffrey Moore sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $84.56, for a total transaction of $126,840.00. Also, CFO Thad Allen Huston sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $81.49, for a total value of $162,980.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,000 shares of company stock valued at $634,715. Company insiders own 0.41% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in LivaNova by 376.8% during the 2nd quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock valued at $165,437,000 after purchasing an additional 1,816,788 shares during the last quarter. Paradice Investment Management LLC raised its holdings in shares of LivaNova by 720.1% in the 3rd quarter. Paradice Investment Management LLC now owns 469,807 shares of the company’s stock worth $34,667,000 after purchasing an additional 412,521 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of LivaNova by 18.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock worth $172,349,000 after purchasing an additional 378,564 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of LivaNova by 1,661.4% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 392,149 shares of the company’s stock worth $28,219,000 after purchasing an additional 369,885 shares during the period. Finally, Primecap Management Co. CA raised its holdings in shares of LivaNova by 148.8% in the 2nd quarter. Primecap Management Co. CA now owns 475,220 shares of the company’s stock worth $34,197,000 after purchasing an additional 284,220 shares during the period. 88.74% of the stock is owned by hedge funds and other institutional investors.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: Stochastic Momentum Index (SMI)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.